Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Aponermin combined with carfilzomid-pomalidomide-dexamethasone (KPd) in patients with relapsed or refractory multiple myeloma: A prospective, open-label, multicenter study

View Full Paper
Ask AI
Bookmark
Share

Authors

DHDonghua HeXHXiaoyan HanMZMingming Zhang

Discussion

Loading...

Member takes

Overview

Prospective study reports 66.7% overall response rate in heavily pretreated RRMM patients, suggesting Aponermin may enhance the KPd regimen.

Key Points

  • Overall response rate was 66.7% after 2 cycles in patients with relapsed or refractory multiple myeloma.
  • Patients included had a median of 4 prior lines of therapy, indicating a heavily treated population.
  • Analysis of responses assessed by the International Myeloma Working Group criteria shows consistent efficacy across different subgroups.
  • Combination Aponermin and KPd exhibited manageable safety, with most adverse events being non-serious.

Cite This Study

He et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df4dhttps://doi.org/10.1182/blood-2025-2276
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study2025
  2. 2Phase 2 study of aponermin +kt-decp in patients(pts) with Relapsed/Refractory multiple myeloma and extramedullary disease2025
  3. 3Real-world safety and efficacy of aponermin and daratumumab-based regimens in patients with multiple myeloma2025
  4. 4Safety and efficacy of carfilzomib-based combinations in relapsed/refractory multiple myeloma patients in a real-world Setting : Results of a french single academic center retrospective study.2025
  5. 5A real-world study on first-line early switch to kpd regimen in the treatment of multiple myeloma patients with suboptimal induction efficacy or intolerance2025